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Background: Traditional Chinese medicine has been widely used for the treatment of recurrent miscarriage in China
and other Asian countries for long time. We conducted this review to systematically summarize the evidences of
Chinese herbal medicine (CHM) for the prevention and treatment of recurrent miscarriage in randomized trials, and
evaluate the effectiveness and safety of CHM compared with placebo or conventional medicine.
Methods: We searched studies in PubMed, ClinicalTrials, the Cochrane Library, CNKI, SinoMed and VIP databases until
December, 2012. Randomized trials on CHM alone or in combination with conventional medicine for recurrent
miscarriage compared with placebo or conventional medicine were included. We evaluated the methodological
quality of each included trials using the Cochrane risk of bias tool.
Results: A total of 41 RCTs (3660 participants) were included. The majority of trials had a high or unclear risk of bias.
CHM used alone or plus progesterone-based treatment showed superior effect over progesterone-based
treatment in improving live birth rate and embryonic developmental state (measured by B ultrasound). However, there
is substantial heterogeneity within each subgroup analysis (I2 ranging from 35% to 71%). CHM plus progesterone and
hCG-based treatment was superior to progesterone and hCG-based treatment in improving the embryonic
developmental state, but not live birth rate. No severe adverse events were reported in relation to CHM.
Conclusions: Some Chinese herbal medicines or in combination with progesterone-based treatment demonstrated
potentially beneficial effect in improving live birth rate and embryonic developmental state for women with recurrent
miscarriage. However, due to the substantial heterogeneity among the herbal interventions and limitations of
methodological quality of the included trials, it is not possible to recommend any specific CHMs for recurrent
miscarriage. Further rigorous clinical trials are warranted to evaluate the efficacy and safety of CHM.
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Pregnancy loss is a common clinical problem in repro-
duction, occurring in 15% ~ 40% of reproductive-aged
women. Recurrent miscarriage, defined as the loss of three
or more consecutive spontaneous abortions [1,2], affects
1% ~ 2% women of reproductive age [2]. Moreover, in clin-
ical practice, many clinicians define recurrent miscarriage
as two or more losses; this increases the prevalence rate to
approximately 5% of all couples trying to conceive [3,4].* Correspondence: jianping_l@hotmail.com
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reproduction in any medium, provided the orRisk factors for recurrent miscarriage varies widely, such as
maternal age, number of previous miscarriages, antipho-
spholipid syndrome, genetic factors, anatomical deformity
of reproductive organs, endocrine disorders, immune fac-
tors, and infective agents, but in more than half of such
patients, no certain diagnosis could be identified [4,5].
Recurrent pregnancy losses could bring physical and
psychological harms to the patients, as well as a heavy
economic burden, and could even lead to family and so-
cial problems. Hence, researches on the prevention and
treatment of recurrent miscarriage are of significantly
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ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recurrent miscarriage is largely unclear, various interven-
tions have been used in clinical practice, but the majority
of them are still lack of sufficient evidence to support
their use to prevent a miscarriage in women with recurrent
miscarriage. Evidence from the guideline for the manage-
ment of recurrent pregnancy loss published by American
Congress of Obstetricians and Gynecologists (ACOG) [1]
and Royal College of Obstetricians and Gynecologists
(RCOG) [6] suggest that, except for the recommendation
of low-dose aspirin plus with low-molecular-weight
heparin for recurrent miscarriage patients with antipho-
spholipid syndrome, there is few good evidence to sup-
port the other commonly used interventions for recurrent
miscarriage; some immunotherapies such as paternal cell
immunisation, third-party donor leucocytes, trophoblast
membranes and intravenous immunoglobulin in women
with previous unexplained recurrent miscarriage do not
improve the live birth rate, and have potentially serious
adverse effects. Observation is a reasonable strategy for
patients, and a subsequent pregnancy will result in a live
birth for about two thirds of couples [1,6,7].
As no curative conventional interventions are available
for the disease, many parents prefer to seek alternative
medicine. In China and other Asian countries, traditional
Chinese medicine (TCM) has been widely used for the
treatment of recurrent miscarriage for a long time. With
the dissemination and application of clinical epidemiology
and evidence-based medicine in TCM during the past two
decades, a series of trials evaluating the efficacy and safety
of Chinese herbal medicine (CHM) for recurrent miscar-
riage were conducted, but the findings have not yet been
systematically summarized. The objective of this review is
to critically appraise the existing randomized clinical trials
(RCTs) on CHM for the prevention and treatment of re-
current miscarriage, and provide evidence-based evalu-
ation on the efficacy and safety of CHM for this condition.
Methods
Study search
A search strategy was designed to search all the available lit-
erature. We searched PubMed, ClinicalTrials, the Cochrane
Library (Issue 10, 2012), the Chinese National Knowledge
Infrastructure Databases (CNKI), the Chinese Science and
Technology Periodical Database (VIP), the Chinese Bio-
medical Database web (SinoMed), and the Wanfang Data-
base, from their inception to December, 2012. There was
no limitation on language or publication type. The
search terms included [“Abortion, habitual” and “Medi-
cine, Chinese Traditional”] as Mesh terms and [“recurrent
miscarriage” or “recurrent pregnancy loss” or “recurrent
spontaneous abortion”] as “all fields” searching in PubMed,
ClinicalTrials, and the Cochrane Library. In the Chinese da-
tabases, we employed recurrent miscarriage and randomiz*as the major search terms with no limitations on the mo-
dalities CHM employed.
Study selection
Two authors (H. Luo and X. Liao) selected the literature
independently. Papers were screened according to the title
and then selected through abstracts. The full texts were
retrieved if they potentially met the inclusion criteria.
Studies meeting the following criteria were included in
this review: (1) type of study: randomized clinical trials
(RCTs); (2) type of participants: females who had a history
of at least two or more miscarriage, and were trying to get
pregnant or were already pregnant; (3) type of interven-
tions: the study was designed to compare the effectiveness
and safety of CHM or CHM plus conventional medicine
with placebo or conventional medicine; (4) type of out-
comes: live birth rate (the primary outcome), embryonic de-
velopmental state (secondary outcome), and adverse events.
The secondary outcome should be measured by type B
ultrasound, presented as effective rate. “Effective” is defined
as normal embryo development with the increasing weeks
of gestation, and “ineffective” is defined as embryo stopping
growing or recurrence of spontaneous abortion.
The following types of studies were excluded: (1) mul-
tiple publications reporting the same data of patients; (2)
lack of basic information on participants or interven-
tions; (3) controlled treatment included CHM therapies;
as in this case, it would be impossible to evaluate the
specific effects of the intervention.
If there was a lack of some important information in
the paper, such as methodology, diagnosis, interventions
and outcomes, we would try to contact the original au-
thors to clarify the data.
Risk of bias assessment
We conducted the selection of studies by using criteria
from the Cochrane Handbook for Systematic Reviews of
Interventions, version 5.0.2 [8]. Full texts were retrieved
for any potentially relevant studies, and then were iden-
tified according to the inclusion criteria. Any disagree-
ments were resolved by discussion or consulting to the
third researcher.
The methodological quality of included RCTs was as-
sessed using Cochrane risk of bias tool. The generation of
the allocation sequence, allocation concealment, blinding
and outcome reporting were taken into account for as-
sessment. All the included trials would be categorized as
low/unclear/high risk of bias: trials that met all the criteria
were categorized as low risk of bias; those that met none
of the criteria were categorized as high risk of bias; and
the others were categorized as unclear risk of bias if insuf-
ficient information was available to make a judgment. Dis-
agreements were consulted to the third author (JP Liu)
to resolve.
Yang et al. BMC Complementary and Alternative Medicine 2013, 13:320 Page 3 of 10
http://www.biomedcentral.com/1472-6882/13/320Data extraction
Two authors (G. Yang and H. Luo) extracted the data inde-
pendently using a pre-designed data form. The following
data were extracted: (1) citations (author, title, journal, year,
issue, volume, and page); (2) methodological characteristics
of trials; (3) participants (sample size, age, causes of recur-
rent miscarriage, and current status of patients); (4) detailed
information of interventions and controls; (5) outcome
measures; (6) a summary of results; and (7) adverse effects.
Data analysis
The data were analyzed using RevMan 5.0 software. The
effect measure was summarized by risk ratio (RR) with a
95% confidence interval (CI). Meta-analysis was used if
the trials were homogeneous on study design, participants,
interventions, control, and outcome measures. We used
fixed effect model unless there are evidence of substantial
heterogeneity where random effect model would be applied
for pooling data. We assessed heterogeneity using both the
I-squared statistic, and considered an I-squared value
greater than 50% indicative of substantial heterogeneity [8].
If sufficient number of trials (i.e., over 10 trials), we would
conduct funnel plot to detect potential publication bias.
Results
Using the search strategy, we identified a total of 307
references. After screening titles and abstracts and ex-
cluded duplicated papers, 57 full papers were downloaded
for eligibility identifying. Finally, 16 studies were excluded
with reasons, and 41 RCTs were included in this system-
atic review (Figure 1).
Description of included trials
All of the 41 trials were conducted in China, and published
in Chinese journals. A total of 3660 women with recurrent
miscarriage were involved, with an average number of 89.3
per trial, ranging from 31 to 185. Among the included trials,
41.5% (17/41) reported participants with the loss of two or
more consecutive spontaneous abortions, and 56.1% (23/
41) reported participants with three or more consecutive
spontaneous abortions. One trial didn’t report the definition
of “recurrent miscarriage”. 25 trials reported the cause of
recurrent miscarriage, including antiphospholipid syndrome
[9-12], negative blocking antibodies [13], luteal phase
defect [14,15], hyperprolactinemia [16], pre-thrombosis
[17], cytomegalovirus infection [18], and unexplained rea-
sons [19-33]. Participants in 26 trials (63.4%, 26/41) were
already pregnant; in 11 trials (26.8%, 11/41) were trying to
be pregnant; females both already pregnant and trying to
be pregnant were included in two trials (4.9%, 2/41)
[34,35]; another two trials (4.9%, 2/41) [22,28] didn’t re-
port this item.
CHM included patent medicine in three trials [16,36,37],
and practitioner-prescribed herbal formula based on TCMsyndrome differentiation in 38 trials, of which 7 trials
[10,13,17,29,32,38,39] prepared the CHMs in hospital prep-
aration room. The preparation of CHM included decoction
(82.9%, 34/41), pill (7.3%, 3/41), granule (4.9%, 2/41), pow-
der (4.9%, 2/41), capsule (2.4%, 1/41), oral liquid (2.4%, 1/
41) and ointment (2.4%, 1/41). The most frequently used
decoction was modified ‘Shou Tai Wan’ (21.9%, 9/41), and
other formulas were prescribed according to the experience
of physicians and clinical presentations/syndromes of the
patients. Five trials [9,12,17,37,40] applied CHMs with the
action of invigorating blood, and the most frequently used
compositions in these CHMs were Radix Angelicae Sinensis
(dang gui) [9,12,17,37,40] and Radix et Rhizoma Salviae
Miltiorrhizae (dan shen) [9,17,40]. The detailed composi-
tions of all CHMs for recurrent miscarriage were presented
as supporting information (see Additional file 1: Table S1).
Conventional medicines included progesterone, human
chorionic gonadotrophin (hCG), heparin sodium, folic
acid, vitamin C, vitamin E, aspirin, prednisone, dydroges-
terone, immunotherapy, and other symptomatic supports.
For treatment durations, 27 trials treated patients from
trials start to the 3rd to 4th month of gestation, or one
week or half a month exceeding the previous miscarriage
time, 7 trials lasted for 10 days to 3 months, and one trial
[41] treated patients till birth, while another 6 trials were
unclear. 21 trials (51.2%, 21/41) reported live birth rate
and the remaining 20 trials (48.8%, 20/41) reported the
status of embryonic development. More details of the tri-
als were presented in Additional file 2: Table S2.
Methodological quality
A majority of trials was of high or unclear risk of bias, indi-
cating poor methodological quality. The randomized alloca-
tion of participants was mentioned in all trials; however,
only 6 trials reported the methods of sequence generation,
including using random number table [14,20,21,37,40] and
card drawing [16], of which none reported allocation con-
cealment. One trial used matched placebos to blind partici-
pants and practitioners [36], in which patients in the
intervention group received both real CHM oral liquid and
placebo of progesterone, while participants in the control
group received both real progesterone and placebo of CHM
oral liquid. The number of dropouts and intention-to-treat
analysis were not reported in all trials. Meanwhile, in 11 tri-
als which recruited the patients trying to get pregnancy,
only two trials reported pregnancy rate [16,18]. None of the
trials reported sample size estimation. The baseline infor-
mation in nine trials not adequately reported the age or
times of previous miscarriage [9,12,26,28,36,38,42-44]. Since
the protocols of all trials were not available, we assessed the
selective reporting bias by comparing their outcome
measures in methods and the reporting of results, and
they had a low risk of bias (Additional file 3: Figure S1
and Additional file 4: Figure S2).
Figure 1 Flowchart of study searching and selection. Presentation of the process of study searching and selection.
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thors of those trials. Since few included papers provided
corresponding authors’ telephone or E-mail address, it
was difficult to contact the original authors, especially for
some papers published a long time ago. So we contacted
the authors of trials which were lack of randomization in-
formation and published after 2005 [9,19,22,23,42,45]. Fi-
nally, three first authors could be contacted. Only one of
the authors responded that a random number table for se-
quence generation was used without allocation conceal-
ment, none of the participants withdrew during the trial,
and no fund supported the trial [23]. Another two authors
rejected to answer our questions. Based on the response,
only one trial [23] was assessed to have a low risk of bias,
and the others have a high or unclear risk of bias.
Effectiveness and safety
We divided the 41 trials into two categories: CHM versus
conventional medicine (17 trials) and CHM plus con-
ventional medicine versus conventional medicine only (24trials). Since there were different combinations of conven-
tional medicine, we divided them into progesterone-based
treatment, progesterone plus hCG-based treatment and
conventional medicine with uncertain effect, and we
reported the findings under the two categories with
subgroups. The detailed effect estimates was presented
in Table 1.
Live birth rate
21 trials reported live birth rate, of which eight trials com-
pared CHM with conventional medicine, and 13 trials
compared CHM plus conventional medicine with conven-
tional medicine.
In trials comparing CHM with conventional medi-
cine, four trials found a superior effect of CHM over
progesterone-based treatment (RR: 1.31, 95% CI: 1.13
to 1.52; I2 = 55%, random effect model), one trial found
CHM was superior to hCG-based treatment. Three tri-
als reported CHM versus conventional medicine with
uncertain effect, and two of them favored CHM. We
Table 1 Effect estimates of Chinese herbal medicines for recurrent miscarriage in 41 randomized trials
Outcomes and comparisons Effect estimate
(Random effect model, 95% CI)
Studies Participants Study ID
Live birth rate
CHM vs CM
CHM vs progesterone-based treatment RR 1.31 [1.13, 1.52]*Δ 4 481 Feng [38], Li [20], Yan [35], Zhu [25]
CHM vs progesterone plus
hCG-based treatment
RR 1.25 [1.06, 1.47]* 1 158 Feng [45]
CHM vs CM with uncertain effect RR 0.97 [0.41, 2.33] 3 214 Huang [41], Li [18], Wang [26]
CHM plus CM vs CM
CHM plus CM vs progesterone-based
treatment
RR 1.17 [1.06, 1.29]*Δ 4 315 Huang [22], Li [46], Li [27], Pan [47]
CHM plus CM vshCG-based treatment RR 1.20 [1.01, 1.43]* 1 75 He WH [19]
CHM plus CM vs progesterone plus
hCG-based treatment
RR 1.08 [0.93, 1.25] 3 148 Cai [48], Tian [16], Zhao [23]
CHM plus CM vs CM with uncertain effect RR 1.55 [1.16, 2.08]*Δ 5 485 He GY [21], Shu [11], Sun [40], Xie [34], Ye [9]
Embryonic developmental state
CHM vs CM
CHM vs progesterone-based treatment RR 1.43 [1.02, 1.99]*Δ 3 253 Wu [32], Xu [33], Yang [36]
CHM vs CM with uncertain effect RR 1.33 [0.99, 1.77]Δ 6 515 Ban [39], Liu [24], Luo [17], Tang [12], Tian [29],
Zhao [49]
CHM plus CM vs CM
CHM plus CM vs
progesterone-based treatment
RR 1.55 [1.23, 1.94]*Δ 2 191 Yang [14], Zou [42]
CHM plus CM vs progesterone plus
hCG-based treatment
RR 1.18 [1.05, 1.33]*Δ 4 252 Hou [31], Li [10], Wang [30], Wang [37]
CHM plus CM vs CM with uncertain effect RR 1.47 [1.03, 2.10]* 5 349 Fan [43], Li [44], Liu [15], Zhang [28], Zhou [13]
Abbreviations: CI confidence interval, *the effect estimate favors experimental group; Δ, result from Meta-analysis; CHM Chinese herbal medicine, CM conventional
medicine, hCG human chorionic gonadotrophin.
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eity (I2 = 93%).
In CHM plus conventional medicine versus conven-
tional medicine category, four trials found a superior ef-
fect of CHM plus progesterone-based treatment over
progesterone-based treatment alone (RR: 1.17, 95% CI:
1.07 to 1.29; I2 = 0%, random effect model), and one trial
favored CHM plus hCG-based treatment over hCG-based
treatment alone. Three trials comparing CHM plus pro-
gesterone and hCG-based treatment versus conventional
medicine demonstrated no significant difference between
groups (RR: 1.08, 95% CI: 0.93 to 1.25; I2 = 40%, random
effect model). Five trials favored CHM plus conventional
medicine with uncertain effect over conventional medi-
cine (RR: 1.55, 95% CI: 1.16 to 2.08; I2 = 80%, random ef-
fect model).
Embryonic developmental state
20 trials reported the embryonic developmental state in
terms of effective rate, of which nine trials compared CHM
versus conventional medicine and 11 trials compared CHM
plus conventional medicine versus conventional medicine
alone.In trials comparing CHM with conventional medicine,
three trials found a superior effect of CHM over conven-
tional medicine (RR: 1.43, 95% CI: 1.02 to 1.99; I2 = 71%,
random effect model), including a matched placebo trial
comparing Yunkang Oral Liquid with progesterone [36];
6 trials found comparing CHM versus conventional
medicine with uncertain effect demonstrated no signifi-
cant difference between two groups (RR: 1.33, 95% CI:
0.99 to 1.77; I2 = 83%, random effect model).
In trials of CHM plus conventional medicine versus
conventional medicine, two trials found a superior effect
of CHM plus progesterone-based treatment over con-
ventional medicine alone (RR: 1.55, 95% CI: 1.23 to 1.94;
I2 = 35%, random effect model). Four trials favored CHM
plus hCG-based treatment (RR: 1.18, 95% CI: 1.05 to
1.33; I2 = 0%, random effect model). Five trials did not
found significant difference between groups except one,
comparing CHM plus conventional medicine with un-
certain effect to conventional medicine alone. We do
not pooled the data due to considerable heterogeneity
(I2 = 90%).
The forest plots of comparison of CHM plus conven-
tional medicine versus conventional medicine alone for
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mental state were shown in Figures 2 and 3 respectively.Adverse events
Five trials reported that no adverse events occurred in
CHM group [18,28,29,36,38]; six trials reported that no
adverse events occurred in both CHM group and con-
ventional group [17,20,21,23,32,44]. Two trials reported
adverse events, including minor nausea in CHM group
[22], and a case of fetal malformation in conventional group
which used progesterone, vitamin E and some sedatives
[35]. The remaining 30 trials did not report the information
of adverse events.Funnel plot
Funnel plot analysis of the thirteen studies which re-
ported live birth rate comparing CHM plus conventional
medicine with conventional medicine was performed toFigure 2 Forest plot of CHM plus CM versus CM for live birth rate. Prese
medicine versus conventional medicine for the outcome of live birth rate.explore publication bias (Figure 4). The plot was asym-
metrical indicating significant bias.Discussion
Summary of findings
Though CHM is widely used for recurrent miscarriage in
China and other eastern countries [50], there has been no
evidence to support the use of CHMs for this disease.
According to this review, several CHMs, such as modi-
fied ‘Shou Tai Wan’ and modified ‘An Tai Yin’, demon-
strated potentially positive effect and safety for recurrent
miscarriage on improving live birth rate and embryonic
developmental state. However, there was considerable
clinical heterogeneity among these “positive” CHMs, due
to ‘modification’ of formula. In addition, the methodo-
logical quality of these trials was generally low. There-
fore, there is insufficient evidence to recommend any
specific CHMs for recurrent miscarriage.ntation of the forest plot of Chinese herbal medicine plus conventional
Figure 3 Forest plot of CHM plus CM versus CM for embryonic developmental state. Presentation of the forest plot of Chinese herbal
medicine plus conventional medicine versus conventional medicine for the outcome of embryonic developmental state.
Figure 4 Funnel plot.
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modified ‘Shou Tai Wan’. In traditional Chinese medicine,
the deficiency of the spleen and kidney is a major reason of
recurrent miscarriage, and ‘Shou Tai Wan’, with the func-
tion of supplementing the kidney, fortifying the spleen,
enhancing qi and nourishing blood, has been used for re-
current miscarriage in TCM since Qing Dynasty [51]. Ac-
cordingly, the majority of CHMs for recurrent miscarriage
in this review were prescribed based on the principle of
supplementing the spleen and kidney.
Limitation of the systematic review
None of the included trials reported negative outcome
and the asymmetry of the funnel plot indicated potential
publication bias in this systematic review, since trials
with positive results are published more easily than those
with negative findings [52]. Although we tried to search
the trials as systematically and comprehensively as possible,
all of the trials were published in Chinese journals. Since
we searched the papers in language of English and Chinese,
papers published in other language, such as Korean and
Japanese (CHM is commonly used in this east-Asia coun-
tries), may not be identified and included in this review,
which may lead to a bias of the results.
There was a high heterogeneity in the 41 included trials:
1) baseline information was not adequately reported in
some trials; 2) interventions differed from each other in
treatment and control groups; comparisons were inappro-
priate in some trials, including using multiple interven-
tions causing the difficulty of evaluating CHM’s specific
effect and safety; 3) some controls with uncertain effect:
some conventional medicines were ineffective or even
harmful, such as phenobarbital [38], since studies proved
that pregnancy women’ exposure to phenobarbital may
causing intelligence deficits in adult [53]; 4) lack of pla-
cebo control; 5) outcomes differed in these trials: only 19
trials reported live birth rate, but other trials had a insuffi-
cient duration of follow-up and couldn’t achieve the final
outcome, limiting the application of their research results.
Implications for future research
For further research, we highlighted four issues which
should be taken into consideration for Chinese medicine
researches: 1) Design and reporting of RCTs on CHM
for recurrent miscarriage should adhere to the CON-
SORT statement [54]: Sample size should be based on
enough statistical power, and calculation of sample size
method should be reported in the text; Randomization
methods need to be described sufficiently, with an ap-
propriate concealment; Baseline information should be
reported in details; 2) Treatment intervention should be
CHM decoction or Chinese patent medicine alone to be
evaluated; if researchers consider a combination of CHM
and conventional medicine, the conventional medicineshould not be a combination of different conventional
treatments, and the same conventional medicine should
be used in both arms; 3) Placebo can be used for control if
the intervention of treatment group is Chinese patent medi-
cine; 4) The course of follow-up should be long enough, so
as to observe and evaluate the end-point outcome (live
birth or abortion) of the disease.
Last but not least, we recommend that trial protocols
of CHM for recurrent miscarriage should be registered
internationally and reported transparently.
Conclusions
Some CHMs or in combination with progesterone-based
treatment, may have beneficial effect on increasing live
birth rate and improving embryonic developmental state
for women with recurrent miscarriage. However, due to
the substantial heterogeneity among herbal interventions,
we should make the interpretation of the findings with
caution. When comparing with progesterone and hCG-
based treatment, CHM plus conventional medicine only
showed superior effect in embryonic developmental state.
In addition, the methodological flaws of the included trials
and inconsistent findings disable us to recommend any
specific CHM for recurrent miscarriage. Further clinical
evidence of robust design is warranted to evaluate the effi-
cacy and safety of CHM for the treatment of recurrent
miscarriage.
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